1
|
Maller T, Jubeh R, Perel N, Barbash IM, Segev A, Kornowski R, Vaknin Assa H, Finkelstein A, George J, Perlman G, Guetta V, Asher E, Karameh H, Glikson M, Dvir D. Large multicenter evaluation of clinical outcomes of transcatheter aortic valve implantation in different age groups: results from the Israeli TAVI registry. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Introduction
Transcatheter aortic valve implantation (TAVI) is becoming the preferred treatment for elderly patients with severe aortic stenosis. Clinical outcomes of these patients according to different age groups and especially in the very old population are under reported.
Purpose
To describe clinical characteristics at baseline, according to different age groups, and to compare clinical outcomes in the very old population with other patients undergoing the procedure.
Methods
Data was extracted from the Israeli National TAVI Registry. Clinical outcomes in very old patients (above the age of 90 years) were compared with younger patients. Multivariable analysis for 30-day and 1-year mortality were performed. Procedural complication was defined as one or more of the following: need for permanent pacemaker, major vascular complication, severe acute kidney injury and major stroke.
Results
A total of 5,936 patients who underwent TAVI from 2008 to 2021 were analyzed (age 81.6±7.1 years, 50.6% female). Patients older than 90 years of age had more comorbidities than the younger population (STS score for mortality 6.4%±3.8% vs. 4.1%±4.8%, p<0.001). Independent correlates for 30-day mortality included STS score (OR=1.01, 95% CI [1.03–1.13], p<0.001) and procedural complication (OR=4.29, 95% CI [2.24–8.20], p<0.0001). Independent correlates for 1-year mortality included chronic obstructive pulmonary disease (OR=1.83, 95% CI [1.28–2.60]; p=0.001), atrial fibrillation (OR=1.71, 95% CI [1.31–2.23]; p<0.001 (STS score); OR=1.13 95% CI [1.09–1.18]; p<0.001), and procedural complication) OR=2.58, 95% [1.89–3.50]; p<0.001).
Conclusions
Although older patients undergoing TAVI had a higher risk profile, short- and long-term survival of these patients were associated significantly more with procedural complications than with patient age. It seems that extreme patient age alone should not be viewed as a consideration for not performing valve replacement, as long as the risk for procedural complications does not seem to be severely elevated.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- T Maller
- Shaare Zedek Medical Center , Jerusalem , Israel
| | - R Jubeh
- Shaare Zedek Medical Center , Jerusalem , Israel
| | - N Perel
- Shaare Zedek Medical Center , Jerusalem , Israel
| | | | - A Segev
- Sheba Medical Center , Ramat Gan , Israel
| | | | | | | | - J George
- Kaplan Medical Center , Rehovot , Israel
| | - G Perlman
- Hadassah University Medical Center , Jerusalem , Israel
| | - V Guetta
- Sheba Medical Center , Ramat Gan , Israel
| | - E Asher
- Shaare Zedek Medical Center , Jerusalem , Israel
| | - H Karameh
- Shaare Zedek Medical Center , Jerusalem , Israel
| | - M Glikson
- Shaare Zedek Medical Center , Jerusalem , Israel
| | - D Dvir
- Shaare Zedek Medical Center , Jerusalem , Israel
| |
Collapse
|
2
|
Karameh H, Harari E, Almagor Y, Jubeh R, Shuvy M, Hellou E, Taha L, Butnaru A, Wolak A, Glikson M, Dvir D. Large comprehensive evaluation of new- vs. old-generation ACURATE neo self-expanding valve during TAVI procedures: a decrease in paravalvular leakage with an increase in post-procedural gradients? Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.1580] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Contemporary data comparing new- versus old-generation transcatheter heart valve (THV) devices are lacking regarding several THV devices. We aimed to compare the safety and efficacy of old-generation device (OGD) ACURATE neoTM versus the newer generation device (NGD) ACURATE neo2TM THVs (Boston Scientific) in patients undergoing transcatheter aortic valve implantation (TAVI).
Methods
An analysis of patients undergoing transfemoral TAVI with old-generation device ACURATE neoTM versus newer generation device ACURATE neo2TM from 2016 to 2021. The primary end-point was early safety events at 30-days post-valve implantation. Significant post-implantation paravalvular leakage (PVL) was considered as ≥moderate.
Results
A total of 249 patients were included in the evaluation; mean age was 81±7.2, and 95 (38.2%) were males. Of the total population 87 (35%) underwent TAVI with the NGD. Early safety events occurred in 21.8% NGD versus 19.1% in OGD (RR= 0.67, P=0.13). Permanent pacemakers were implanted within 30 days in 4.6% versus 6.2% in NGD versus OGD respectively (RR=1.343, P=0.77). Major vascular complications occurred in 5.7% in NGD versus 9.4% in OGD 9.4% (RR=1.6, P=0.46). More than mild PVL occurred significantly more often in OGD (P<0.0001). Echocardiographic mean gradient post-procedure was 9 mmHg± 5 in OGD versus 11±4 mmHg in the NGD (P=0.0159).
Conclusion
New-generation ACURATE neo2TM devices were associated with less significant PVL. However, this new generation valve was also associated with higher residual gradients. This trend of decrease in PVL with an increase in gradients will be further studied.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- H Karameh
- Shaare Zedek Medical Center, The Jesselson Integrated Heart Center , Jerusalem , Israel
| | - E Harari
- Shaare Zedek Medical Center, The Jesselson Integrated Heart Center , Jerusalem , Israel
| | - Y Almagor
- Shaare Zedek Medical Center, The Jesselson Integrated Heart Center , Jerusalem , Israel
| | - R Jubeh
- Shaare Zedek Medical Center, The Jesselson Integrated Heart Center , Jerusalem , Israel
| | - M Shuvy
- Shaare Zedek Medical Center, The Jesselson Integrated Heart Center , Jerusalem , Israel
| | - E Hellou
- Shaare Zedek Medical Center, The Jesselson Integrated Heart Center , Jerusalem , Israel
| | - L Taha
- Shaare Zedek Medical Center, The Jesselson Integrated Heart Center , Jerusalem , Israel
| | - A Butnaru
- Shaare Zedek Medical Center, The Jesselson Integrated Heart Center , Jerusalem , Israel
| | - A Wolak
- Shaare Zedek Medical Center, The Jesselson Integrated Heart Center , Jerusalem , Israel
| | - M Glikson
- Shaare Zedek Medical Center, The Jesselson Integrated Heart Center , Jerusalem , Israel
| | - D Dvir
- Shaare Zedek Medical Center, The Jesselson Integrated Heart Center , Jerusalem , Israel
| |
Collapse
|
3
|
Karameh H, Taha L, Karmi M, Hamayel K, Perel N, Steinmetz Y, Levi N, Shaheen F, Manassra M, Maller T, Glikson M, Asher E. Outcomes of patients treated with blood transfusion in a contemporary tertiary intensive cardiac care unit. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.1485] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Different trials showed that patients treated with blood transfusion (BT) have unfavorable prognosis regarding outcomes and mortality. Nevertheless, outcomes in patients treated with BT hospitalized in a contemporary tertiary intensive cardiac care unit (ICCU) is limited.
Objective
To determine mortality rate in patients treated with BT in a contemporary tertiary ICCU.
Methods
A prospective single center study to evaluate short- and long-term mortality rate of patients treated with BT between January 2020 and December 2021 in a tertiary ICCU.
Outcomes
During the study period 2132 consecutive patients were admitted with a mean age of 66.9±16 and 650 (30.5%) of them were women. Of the total population, 108 (5%) patients were treated with BT (BT-group) during their hospitalization. Patients were followed-up for 2 years with a median [IQR] follow up time of 82.5 [12.25–240.50] days in BT-group vs. 138.5 [34–325, 75] days in the non-BT (NBT) group. Mean age was 73.81±14 years in BT-group vs. 66.59±16 years in NBT-group, p<0.0001. There was a higher rate of female gender in the BT-group 48.1% vs. 29.5% in the NBT, p<0.0001. Crude mortality rate was 29.6% in BT-group and 9.2% in NBT-group, p<0.0001. Median [IQR] length of stay was 5 [2–6] days in BT-group vs. 3 [2–4] days in the NBT-group. Multivariate Cox analysis for (Female gender, prior trans-catheter aortic valve replacement, prior cardiac intervention, sepsis, history of congestive heart failure, pulmonary hypertension, pacemaker implantation and anemia) showed that BT was independently associated with more than two folds the mortality rate [HR=2.19 95% CI (1.47–3.62)] as compared with the NBT-group, p<0.0001. Receiver operating characteristic curve (ROC) was plotted for multivariable analysis and showed area under curve (AUC) of 0.8, 95% CI [0.760–0.852].
Conclusion
Even in contemporary tertiary ICCU, with advanced technology, equipment and delivery of care, BT remains a strong predictor for short- and long-term mortality.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- H Karameh
- Shaare Zedek Medical Center, The Jesselson Integrated Heart Center , Jerusalem , Israel
| | - L Taha
- Shaare Zedek Medical Center, The Jesselson Integrated Heart Center , Jerusalem , Israel
| | - M Karmi
- Shaare Zedek Medical Center, The Jesselson Integrated Heart Center , Jerusalem , Israel
| | - K Hamayel
- Shaare Zedek Medical Center, The Jesselson Integrated Heart Center , Jerusalem , Israel
| | - N Perel
- Shaare Zedek Medical Center, The Jesselson Integrated Heart Center , Jerusalem , Israel
| | - Y Steinmetz
- Shaare Zedek Medical Center, The Jesselson Integrated Heart Center , Jerusalem , Israel
| | - N Levi
- Shaare Zedek Medical Center, The Jesselson Integrated Heart Center , Jerusalem , Israel
| | - F Shaheen
- Shaare Zedek Medical Center, The Jesselson Integrated Heart Center , Jerusalem , Israel
| | - M Manassra
- Shaare Zedek Medical Center, The Jesselson Integrated Heart Center , Jerusalem , Israel
| | - T Maller
- Shaare Zedek Medical Center, The Jesselson Integrated Heart Center , Jerusalem , Israel
| | - M Glikson
- Shaare Zedek Medical Center, The Jesselson Integrated Heart Center , Jerusalem , Israel
| | - E Asher
- Shaare Zedek Medical Center, The Jesselson Integrated Heart Center , Jerusalem , Israel
| |
Collapse
|
4
|
Turyan Medvedovsky A, Taha L, Farkash R, Bayya F, Dadon Z, Steinmetz Y, Shaheen F, Karameh H, Glikson M, Asher E. D-dimer as a prognostic factor in patients admitted to a tertiary care intensive coronary care unit. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.1130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
D-dimer is a small protein fragment and is a product of fibrinolysis. A high levels of D-dimer have been suggested as a prognostic factor in cancerous and other critically ill patients. We aimed to evaluate D-dimer levels and outcomes of critically ill patients admitted to a tertiary care intensive coronary care unit (ICCU).
Material and method
All patients admitted to the ICCU at our Medical Center between January 1, 2020 and December 31, 2020 were included in the study. Patients were divided into 2 groups according to their D-dimer level on admission. Low D-dimer level <500 ng/ml, and high D-dimer level ≥500 ng/ml. Survival, in-hospital interventions and complications were compared.
Results and discussion
Overall 1,082 consecutive patients were included, mean age was 67 (±16), 70% were males. Of them 296 (27.4%) had low D-dimer level and 663 (61.3%) had high D-dimer level. Patients with high D-dimer level were older as compared to patients with low D-dimer level (mean age 70.4±15 and 59±13 years respectively, p=0.004), had significantly higher rate of female gender (35.9% vs 15.9% respectively, p<0.0001) and significantly higher rate of any prior cardiac interventions prior to their admission (26.7% vs 4.4% respectively, p<0.0001). Interestingly, patients with high D-dimer level had significantly lower rate of any acute coronary syndrome (ACS) as compared with the low D-dimer group (25.7 vs 66.4% respectively, p<0.0001) and lower rate of smokers (22.5 vs 45.6% respectively, p<0.0001). All 11 post-COVID-19 patients had high D-dimer level on admission.
A multivariate Cox proportional hazards analysis for mortality, adjusted for age, gender, risk factors for cardiovascular disease, ejection fraction<40 found that high D-dimer level was independently associated with higher mortality rates (HR=5.8; 95% CI; 1.7–19.1; p=0.004) as shown in Figure 1.
Conclusion
Elevated D-dimer levels on admission in ICCU patients is a poor prognostic factor of in-hospital morbidity and mortality in the first year following hospitalization.
Funding Acknowledgement
Type of funding sources: None. Cumulative survival according to d-Dimer
Collapse
Affiliation(s)
- A Turyan Medvedovsky
- Shaare Zedek Medical Center, The Jesselson Integrated Heart Center, Jerusalem, Israel
| | - L Taha
- Shaare Zedek Medical Center, The Jesselson Integrated Heart Center, Jerusalem, Israel
| | - R Farkash
- Shaare Zedek Medical Center, The Jesselson Integrated Heart Center, Jerusalem, Israel
| | - F Bayya
- Shaare Zedek Medical Center, The Jesselson Integrated Heart Center, Jerusalem, Israel
| | - Z Dadon
- Shaare Zedek Medical Center, The Jesselson Integrated Heart Center, Jerusalem, Israel
| | - Y Steinmetz
- Shaare Zedek Medical Center, The Jesselson Integrated Heart Center, Jerusalem, Israel
| | - F Shaheen
- Shaare Zedek Medical Center, The Jesselson Integrated Heart Center, Jerusalem, Israel
| | - H Karameh
- Shaare Zedek Medical Center, The Jesselson Integrated Heart Center, Jerusalem, Israel
| | - M Glikson
- Shaare Zedek Medical Center, The Jesselson Integrated Heart Center, Jerusalem, Israel
| | - E Asher
- Shaare Zedek Medical Center, The Jesselson Integrated Heart Center, Jerusalem, Israel
| |
Collapse
|